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Abstract The mechanisms of glyceryl trinitrate (GTN)-
induced headache are not fully elucidated. In this study we
administered GTN 0.5 lg/kg/min i.v. for 20 min in six
healthy volunteers. Before, during and 60 min after the
infusion, we investigated regional cerebral blood flow
(rCBF), cerebral blood volume (CBV), both estimated with
SPECT, and blood flow velocity (BFV) in the middle
cerebral artery (MCA), measured with transcranial Dopp-
ler. Headache was scored on a numerical verbal rating (0–
10) scale. rCBF was unchanged, CBV was slightly
increased (13%) during GTN infusion, whereas BFV
decreased both during (20%) and 60 min (15%) after GTN.
Headache was short-lived and maximal during infusion.
This discrepancy of time-effect curves for the effect of
GTN on headache and dilatation of MCA indicates that
MCA is most likely not the primary source of pain in GTN-
induced headache. The time-effect curves for the effect of
GTN on headache and on dilation of MCA differed
markedly. This indicates that MCA is most likely not the
primary source of pain in GTN-induced headache.
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Introduction
The glyceryl trinitrate (GTN) headache model with intra-
venous administration of the drug is well established [1–4],
and has been used to evaluate acute and prophylactic anti-
migraine drugs [5–9]. GTN causes an immediate mild to
moderate headache during infusion in normal subjects [1].
Migraine patients are supersensitive to GTN [3] and GTN
causes a delayed headache in 80% of patients. This head-
ache resembles the usual migraine attacks [2, 10] the
patients suffer.
The cause of pain in the NO-induced headache is still
not fully elucidated. In the present study, we therefore
investigated the effect of intravenous GTN in healthy
subjects on intracranial hemodynamics: regional cerebral
blood flow, cerebral blood volume and blood flow velocity
in the middle cerebral artery.
Methods
Material and measurements
Six healthy subjects, F:M = 2:4, with a mean age of
27.5 years (range 22–38 years) participated in the study.
Subjects with migraine and subjects with more than one
tension-type headache day per month were excluded. The
subjects were to be free from any medication for at least a
week. They arrived in the laboratory in the morning after
abstaining from alcohol and caffeine for 12 h. Following
the placing of a catheter in a cubital vein, they rested supine
for 30 min after which baseline measurements were done.
Glyceryl trinitrate in a dose of 0.5 lg/kg/min was
infused intravenously via the catheter in a cubital vein for
20 min by a volume-directed pump (Braun perfusor).
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Headache was scored on a numerical verbal rating scale
from 0 to 10 (0 = no headache and 10 = worst possible
pain) [1] every 10 min before, during, and up to 60 min
after GTN infusion.
The time-averaged mean of the maximal blood veloci-
ties (Vmean) in the right middle cerebral arteries (MCA) was
measured with transcranial Doppler (EME TC28) [11]. The
fixpoint measurements of Vmean was a point along the
MCA, which was free of the bifurcation between the MCA
and the anterior cerebral artery, but as close to it as possible
[12]. Due to technical reasons and limitation of space in the
scanner, the measurements were performed only on the
right side.
Regional cerebral blood flow (rCBF) was measured with
a highly sensitive, brain-dedicated, fast-rotating, single
photon emission computerised tomograph (Tomomatic
232). Each study lasted 4.5 min. A mixture of atmospheric
air and 133Xenon was re-breathed during the first 1.5 min
through a closed system from a 4-litre reservoir (740 Mbq/
l). During the last 3 min the 133Xenon mixture was expired
against atmospheric air. rCBF was recorded simultaneously
in two slices positioned 50 and 90 mm above and parallel
to the orbito-meatal plane. Each slice was 16-mm thick and
the distance between the centres of slices was 40 mm. The
full width half maximum resolution of the instrument is
about 16 mm in the horizontal plane. rCBF was calculated
according to Celsis et al. [13].
A fixed matrix of regions of interest was superimposed
on the rCBF picture. The shape and size were fitted to the
outlines of the brain excluding extracranial flow and
regional mean values were calculated within the predefined
regions of interest. The matrix was divided into regions of
interest representing the hemispheric rCBF regions and the
vascular territories of supply by the anterior-, middle- and
posterior cerebral arteries. The maximum whole body
radiation was approximately 0.6 mSV per rCBF measure-
ment [14]. rCBF and CBV were measured simultaneously
with a highly sensitive, brain-dedicated, fast-rotating single
photon emission computerized tomograph, SPECT,
equipment (Tomomatic 232) with dual energy window
facilities enabling separation of peak energies from Tc-
99 m and Xe-133. rCBF was measured after Xe-133
inhalation and with 4 1/2 min data sampling. CBV was
recorded after intravenous injection of Tc-99 m labeled
erythrocytes [14] and data were corrected for physical and
biological decay. Mean rCBF and CBV values from the
MCA perfusion territory were calculated from a transverse
section of the brain obtained 50 mm above the orbito-
meatal plane. During the rCBF measurements end-expira-
tory pCO2 was monitored using a capnograph. Data were
corrected for pCO2. Heart rate and blood pressures were
measured every 2 min, except during the rCBF measure-
ments, with an automatic inflatable arm cuff (Tonoprint)
during the GTN infusion and thereafter every 5 min. Blood
samples for determination of counts in the blood were
collected at 0, 15, 30, 60, 120, 150 and 180 min.
Vmean, rCBF and CBV were measured before and after
20 min of GTN infusion and 60 min after the infusion.
Statistical evaluation
Responses were calculated in percent of baseline and
expressed as mean and standard error of the mean (±SEM).
Statistical analysis was done with paired t test. P \ 0.05
was considered statistically significant.
Results
During GTN infusion five of six subjects experienced
headache. The median maximum headache score was 3
(range 0–5). The median headache was 0 (range 0–1)
60 min after termination of the infusion. The cerebral
hemodynamic response was, however, the same in all
subjects. The cerebral blood volume was slightly increased
13 ± 2% (mean SEM) during GTN infusion (P \ 0.05)
and returned to baseline, -0.3 ± 3%, 60 min after the end
of infusion (Fig. 1). The regional cerebral blood flow
(rCBF) in the perfusion territory of the middle cerebral
artery (MCA) was used, and rCBF values from the second
and third measurements were corrected 2% for each mmHg
the end-tidal pCO2 deviated from the control value. There
were no significant changes in rCBF during and after GTN
Fig. 1 The effect of glyceryl trinitrate (0.5 lg/kg/min) i.v. for
20 min in six healthy volunteers on cerebral blood volume, regional
cerebral blood flow and blood flow velocity in the middle cerebral
artery
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in fusion (Fig. 1). The mean maximal velocity (base-
line = 68 ± 3 cm/s) in the MCA decreased by 20%
(P \ 0.05) during infusion (from 68 ± 3 to 55 ± 5 cm/s)
and was still decreased by 15% (56 ± 5 cm/s, P \ 0.05)
60 min after infusion (Fig. 1).
Mean systolic BPs were 116, 119 and 120 mmHg
(P = 0.42). Mean diastolic BPs were 72, 84, and
84 mmHg (P = 0.013). Mean heart rate, 69, 80 and
66 bpm, was unchanged (P = 0.10).
Discussion
Glyceryl trinitrate, an exogenous nitric oxide-donor, is
known to cause headache as a side effect when used in
cardiovascular diseases [15]. A headache model with
intravenous GTN has been developed and evaluated [1–3,
5–10]. The bioavailability after sublingual GTN (0.4 mg)
was 36 ± 25% (mean ± SD), range from 3 to 113% [16].
The time to peak concentration also varied considerably
[16]. In our work with the experimental headache model
we have therefore chosen to use intravenous administration
of GTN, in order to decrease variability of doses given.
In healthy subjects the headache is dose-dependent with
a ceiling effect at 0.5 lg/kg/min [1]. Migraine patients are
more sensitive to GTN than tension-type headache patients
and controls [17]. The cause of headache in the GTN
model is not fully elucidated and it has been suggested that
GTN-induced headache is caused both by vascular and by
neuronal effects of NO [18, 19].
In the present study five of six subjects experienced
headache during the GTN infusion. However, GTN induced
equal hemodynamic responses in all subjects. Median
maximal headache score was 3, and the headache decreased
when the infusion stopped. That the bother of lying in the
scanner amplified the induced headache, cannnot be ruled
out. The headache did not fulfil the criteria for migraine,
and no delayed headache was observed, as can be observed
when GTN is administered to migraine patients [2].
Changes in regional cerebral blood flow (rCBF) are
unlikely to cause headache. Thus during attacks of
migraine with aura there is oligemia when the headache
begins and there is a late hyperemia which persists after the
headache [20]. In the present study, rCBF was unchanged
during headache induced by GTN (Fig. 1). Similar results,
that is unchanged CBF after GTN, were found in one
SPECT study [21] and one PET study [22]. In one PET
study [23] a 23% increase in CBF was found after GTN.
This PET examination [23] showed, however, a decrease in
occipital rCBF and it is unclear how a general vasodilatator
like GTN should cause regional changes in CBF.
This is the first time cerebral blood volume (CBV) after
GTN has been investigated. GTN is a potent dilator of
peripheral veins [24]. CBV was slightly but statistically
significantly increased (13%). Clinically, it is observed in
migraine that headache is usually aggravated by coughing,
straining, or undergoing the Valsalva test, which could infer
a venous component to the migraine attack [25, 26]. We did
not test for this during the GTN-headache. Applying
pressure on the internal jugular veins (Queckenstedt’s
manoeuvre) during migraine attacks did cause an increase
in migraine pain in two studies [27, 28] whereas this was not
the case in one study [29]. This indicates that there could be
a venous component to migraine pain.
Although the Doppler technique does not allow direct
measurements of the diameter of the middle cerebral artery
(MCA), the relative change in diameter can be estimated
from the relation: regional cerebral blood flow
(rCBF) = mean velocity 9 cross sectional area of the artery
[21, 30]. When rCBF is unchanged (Fig. 1) a decrease in
Vmean, as in the present study (Fig. 1), will indicate a dila-
tation of MCA. The decrease in mean blood flow velocity in
MCA (Fig. 1) was still present 60 min after GTN infusion
indicating dilatation. In contrast, the headache had disap-
peared at this time point making it unlikely that dilation per
se of MCA is the cause of NO-induced headache. This is
supported by findings in another study on GTN, where MCA
velocities remained decreased (14%, P \ 0.001) at the time
of headache resolution [31]. In addition, dilation of the MCA
outlasted the headache response after intravenous dipyrid-
amole [32] and sildenafil-induced migraine in migraine
patients, but did not affect MCA velocity [33].
A limitation of this study is the lack of a placebo-control
but it was not considered feasible to expose the healthy
subjects to the double dose of radiation from a total of six
SPECT examinations.
In conclusion, regional cerebral blood flow was
unchanged after GTN whereas the middle cerebral artery
was dilated after GTN. However, because of the dis-
crepancy of the time-effect curve for dilation of MCA and
the effect on headache the dilation of the MCA is unlikely
to cause NO-induced headache. Alternative causes for
headache such as an effect of NO on extracerebral arteries
or an effect of NO on perivascular nerves should be
investigated.
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